An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tandem Diabetes Care to Present at the 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will present an update on Wednesday, January 11, 2023, at 8:15 PM Eastern Time. The presentation will be available via a live webcast, with an archived recording accessible for 30 days on the company’s Investor Center website. Tandem Diabetes Care focuses on innovative insulin delivery solutions and is known for its t:slim X2 insulin pump featuring Control-IQ technology.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15pm Eastern Time (5:15pm Pacific Time).
The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.
Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
